ArticleActa parasitologica2026
Modulation of Oxidative Stress, Inflammatory Cytokines, and Mucosal Immunity by Green Synthesized Zinc Nanoparticles in Giardia Infection in Mice.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiardiasis remains one of the most important intestinal infections and common drugs such as metronidazole (MET), especially at therapeutic doses, are associated with side effects and drug resistance. The aim of this study was to investigate the efficacy of zinc nanoparticles synthesized with Astragalus ecbatanus extract in the treatment of a mouse model of giardia.
methodsIn this study, 72 male Balb/C mice were randomly divided into nine different groups, including a healthy control group, an infected control group, a group receiving MET at a dose of 15 mg/kg, three groups receiving ZN as monotherapy at doses of 2.5, 5, and 10 mg/kg, and three groups receiving combination therapy (ZN plus MET at a dose of 7.5 mg/kg). After seven days of treatment, various indicators, including the number and survival of Giardia cysts in feces, serum electrolyte concentrations, oxidative stress parameters including malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx), as well as the expression of cytokine genes (IL-1β, TNF-α, and IL-10), the level of secretory IgA in intestinal tissue, and biochemical indicators of hepatotoxicity and renal toxicity, were measured and analyzed.
resultsThe prepared nanoparticles had a size between 15 and 70 nm and a zeta stability of - 19.6 mV. Treatment with ZN significantly reduced the number of cysts; doses of 2.5, 5 and 10 mg/kg excreted 366.6, 89.9 and 39.9 cysts less than the infected control (726.6 cysts), respectively. Cyst survival also decreased by 50.2%, 64.6% and 82.7%, respectively. The combination of ZN with low dose MET completely eliminated the infection. Also, sodium increased from 56.8 to 89.6-115.9 mmol/L and to 130.3 mmol/L in the combination treatment; potassium also increased from 1.36 to 2.66-3.54 mmol/L and to 4.1 mmol/L in the combination treatment. MDA levels decreased by 1.69-1.82 U/mg and SOD increased by 51.3-56.6 U/mg. Cytokine analysis revealed strong anti-inflammatory effects: IL-1β decreased to 1.21- and 1.13- fold, TNF-α decreased to 1.31- and 1.18- fold, while IL-10 increased up to 3.91- fold in ZN + MET groups. sIgA levels markedly increased (up to 312.3 pg/mL vs. 212.3 pg/mL in full-dose MET). Liver/kidney markers showed no significant toxicity (P > 0.05).
conclusionGreen-synthesized zinc nanoparticles derived from A. ecbatanus showed significant therapeutic effects against giardiasis, particularly in combination with low-dose metronidazole. Treatment reduced cyst burden, improved oxidative stress and inflammatory markers, and enhanced mucosal immunity. These findings suggest a dual antiparasitic and host-modulatory role. However, further mechanistic studies and clinical validation are required to confirm their therapeutic potential.
Indexed as
Identifiers
42184062What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.